Can radium-223 be given to prostate cancer patients with a history of visceral metastatic disease?

Radium-223 is a bone-targeted radiopharmaceutical. In the ALSYMPCA trial, patients with visceral metastases or lymphadenopathy>3cm were excluded. However, if a patient with mCRPC has visceral disease that resolved with previous treatment, and now has progressive osseous metastases, it would be very ...